Introduction
============

Age-related macular degeneration (AMD) is one of the most common causes of irreversible visual loss among the elderly in developed countries [@B1],[@B2]. AMD is clinically classified as exudative (wet) or non-exudative (dry) AMD. More than 90% of AMD are non-exudative in form, for which there is no current effective treatment available [@B3]. Clinical features of this dry form of AMD are pigmentary changes of the retinal pigment epithelium (RPE) and accumulation of drusen between the RPE layer and Bruch\'s membrane. Although the exact pathogenesis of dry AMD is still not clear, dysfunction of RPE cells leading to secondary photoreceptor loss is suggested as a pathological cause of AMD development [@B4].

The etiology of AMD has been attributed to multiple factors (genetic, environmental, behavioral, and nutritional). However, numerous studies have suggested that aging is the most powerful single factor affecting AMD development [@B5]. One of the causative factors of age-related diseases is oxidative stress, which refers to cellular damage caused by reactive oxygen species (ROS) [@B6]. Oxidative stress with impaired free-radical scavenging has also been implicated in AMD and is known to play a significant role in the development of RPE dysfunction, degeneration, and death during aging [@B7]. RPE phagocytosis of the photoreceptor outer segment, light irradiation of melanin, and photoexcited pigment lipofuscin produce hydrogen peroxide (H~2~O~2~), a ROS to which RPE cells are particularly vulnerable [@B8]. Many previous *in vitro* studies demonstrated that oxidative stress from H~2~O~2~ leads to RPE cell death by causing preferential damage to its mitochondrial DNA [@B8]-[@B10]. Thus, various approaches to protecting RPE cells from oxidative stress have been investigated to slow AMD progression. The protective effects of antioxidants on AMD progression are also clinically supported by epidemiological evidence from two large-scale trials: an age-related eye disease study (AREDS) and AREDS2 [@B11], [@B12]. Daily oral supplementation with antioxidant vitamins and minerals is reportedly effective in reducing the risk of developing advanced AMD by 25% at 5 years.

Well-known antioxidants include polyphenols, which are naturally occurring compounds present mainly in plants, vegetables, and fruits. Polyphenols are a secondary metabolite of plants and are excellent antioxidants, capable of neutralizing the reactivity of ROS produced as byproducts via various metabolic pathways. Recently, their biological action as antioxidants has been widely investigated, due to their protective effects against various age-related degenerative disorders, such as cancer, cardiovascular disease, diabetes, and AMD [@B13]-[@B16].

The leaves of *Melissa officinalis L.*, commonly known as lemon balm, have been used in traditional phytomedicine since ancient times, and have been prescribed for their tonic, antispasmodic, carminative, anxiolytic, sedative, mood-altering, and memory-enhancing effects [@B17]-[@B19]. Numerous investigations have demonstrated that this medicinal herb also has antiviral, neuroprotective, antitumoral, and antiangiogenic effects [@B20]-[@B23]. Recently, it was shown that extracts of *M. officinalis L*. exhibit antioxidant and free-radical scavenging activities [@B24].

However, it is not known whether *M. officinalis L.*extracts can protect human RPE cells against oxidative stress. Therefore, in the present study, we investigated the cytoprotective effect of the extract in oxidatively stressed human RPE cells, through the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway.

Materials and Methods
=====================

Cell culture
------------

Human RPE cell line ARPE-19 was purchased from the American Type Culture Collection (Manassas, VA, USA). ARPE-19 cells were routinely cultured in Dulbecco\'s modified Eagle\'s Medium/Nutrient Mixture F-12 (DMEM/F12, Gibco Life Technologies, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin in a 37°C incubator under a humidified atmosphere containing 5% CO~2~. ARPE-19 cells within 10 passages from the time of purchase were used.

Drugs
-----

*Melissa officinalis L*. leaves were purchased from Alfred Galke GmbH (Harz, Germany). *M. officinalis L*. extract (ALS-L1023; AngioLab Inc., Daejeon, Korea) was manufactured from the leaves of *M. officinalis L*. using activity-guided fractionation. Briefly, dried *M. officinalis L.* leaves were extracted with aqueous ethanol. The extracts were filtered and concentrated. The concentrated ethanol extract was fractionated with ethyl acetate, further concentrated, and then dried to a powder form. ALS-L1023 was then dissolved in dimethyl sulphoxide (DMSO; Sigma, St. Louis, MO, USA) for *in vitro* testing.

Cell viability assay
--------------------

RPE cell viability was evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. ARPE-19 cells were plated in 96-well microplates at a density of 1 × 10^5^ cells/well. The ARPE-19 cells were then treated with different concentrations of H~2~O~2~ (0-0.5 mM) and ALS-L1023 (6.25-200 µg/mL). Pre-treated ARPE-19 cells with ALS-L1023 were incubated for 24 h, followed by a 4 h-exposure of H~2~O~2~ (0.5 mM). MTT solution was added (10 μL/well), and the cells were then incubated for 4 h at 37°C. The absorbance was measured at 450 nm by a microplate reader (Model 680; Bio-Rad, Hercules, CA, USA). All experiments were performed in triplicate. In each experiment, a minimum of three wells per treatment were used. The absorbance values were expressed as a percentage of the control condition (representing 100% cell viability). The relative cell viability was defined as the absorbance of treated wells divided by that of the control.

Flow cytometry analysis for cell apoptosis
------------------------------------------

The cytoprotective effect of ALS-L1023 was evaluated by fluorescence-activated cell sorting (FACS) using a propidium iodide (PI) solution and Annexin V. ARPE-19 cells were grown on a six-well plate at a density of 2 × 10^5^cells/well and treated with or without ALS-L1023 for 24 h, before treatment with 0.5-mM H~2~O~2~ for 4 h. The cells were washed twice and collected with phosphate-buffered saline (PBS). ARPE-19 cells were detached with trypsin-EDTA, resuspended in a fresh culture medium, and stained with PI and Annexin V (BD Biosciences, San Jose, CA, USA). Apoptotic ARPE-19 cells were sorted by FACS (BD FACSCanto II flow cytometry, BD Biosciences). PI-positive and Annexin V-positive cells were quantified after gating using forward and side scattering. The results are expressed as the percentage of Annexin V-stained cells. All experiments were performed in triplicate.

Intracellular ROS measurement
-----------------------------

The intracellular levels of ROS were measured using ROS detection reagents (2′,7′-dichlorodihydrofluorescein diacetate, H~2~DCF-DA, Invitrogen, Carlsbad, CA, USA). This measurement is based on ROS-dependent oxidation of H~2~DCF-DA to 2\',7\'-dichlorodihydrofluorescein (DCF). ARPE-19 cells were incubated with 10 μM of H~2~DCF-DA for 30 min at 37°C, then detached with trypsin/EDTA, washed, and re-suspended in PBS (1 × 10^6^ cells/mL). The fluorescence intensity of 10,000 cells was analyzed using flow cytometry at excitation and emission wavelengths of 488 and 525 nm, respectively. Untreated cells served as the control. The results were expressed as the fluorescence intensity of DCF with respect to that of the control. Experiments were performed in triplicate.

Caspase activity assay
----------------------

Caspase-3/7 activity was determined using an assay kit (CaspaTag Caspase-3, 7 In Situ Assay Kit, Merck KGaA, Darmstadt, Germany). ARPE-19 cells (1 × 10^5^ cells) were incubated with ALS-L1023 (100 µg/mL) for 24 h, before a 4-h exposure to H~2~O~2~ (0.5 mM). According to the manufacturer\'s instruction, cells were incubated with green fluorochrome-labeled inhibitors of caspases (FLICA) (FAM-VAD-FMK) at 37°C for 1 h. After washing, the fluorescence released by active caspase-3 or caspase-7 was measured in a 96-well plate, using an excitation wavelength of 490 nm and an emission wavelength of 520 nm in a fluorometric plate reader (Envision Multi-label Plate Reader; Perkin Elmer, Waltham, MA, USA). Three independent experiments were performed.

Western Blot Analysis
---------------------

Standard Western blot analysis methods were used. Briefly, ARPE-19 cells were treated with or without ALS-L1023 (100 µg/mL), before exposure to H~2~O~2~ (0.5 mM). After 4 h, the ARPE-19 cells were harvested and pooled in 100 µL of a lysis buffer (Pro-prep Protein Extraction Solution, iNtRON Biotechnology, Korea). Cell lysates were centrifuged at 13,000 rpm for 15 min at 4°C, and the supernatants collected. After measuring the protein concentration (Bicinchoninic Acid Protein Assay Kit, Pierce, Rockford, IL, USA), equal amounts of protein were separated by electrophoresis on a 10% SDS-polyacrylamide gel and transferred electrophoretically to a nitrocellulose membrane (Bio-Rad). After blocking with a 3% bovine serum albumin solution, the membrane was incubated overnight at 4°C. Antibodies used in the Western blot assay included an anti-PARP antibody (Cell Signaling, Danvers, MA, USA) and an anti-cleaved PARP antibody (Cell Signaling) to detect the total full-length and cleaved forms of PARP, respectively, an anti-phospho Akt antibody (Cell Signaling) and an anti Akt antibody (Cell Signaling); β-actin served as an internal control. The intensity of the signals was recorded and quantified by a molecular imaging system (Molecular Imager ChemiDoc XRS+, Bio-Rad).

Statistical Analysis
--------------------

Data are presented as means ± SD. The SPSS software package (ver. 17.0; SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Statistical significance was determined using an unpaired t-test. P values \< 0.05 were considered statistically significant.

Results
=======

Cytotoxic effects of ALS-L1023 on RPE cells
-------------------------------------------

We first investigated the potential cytotoxicity of ALS-L1023 on human RPE cells. The viability of ARPE-19 cells was evaluated using MTT assay with different concentrations of ALS-L1023. ALS-L1023 did not affect cell viability for concentrations \> 6.25-150 µg/mL, as shown in Figure [1](#F1){ref-type="fig"}A. However, at a concentration of 200 µg/mL, a slight decrease in cell viability was observed (79.5 ± 4.5%). As such, concentrations of ALS-L1023 \< 150 µg/mL were used in the following experiments. To choose the appropriate concentration of H~2~O~2~, dose-response tests were performed. Figure [1](#F1){ref-type="fig"}B shows that cell viability decreased significantly as the concentration of H~2~O~2~ increased. H~2~O~2~ treatment using concentrations of 0.0625, 0.125, 0.25, and 0.5 mM resulted in 90.2 ± 3.4%, 80.1 ± 3.6%, 61.2 ± 2.9%, and 28.5 ± 4.2% cell viability, respectively. Therefore, a concentration of 0.5-mM H~2~O~2~ was used as the working concentration in the following experiments.

ALS-L1023 inhibits H~2~O~2~-induced RPE cell death
--------------------------------------------------

Next, we investigated whether ALS-L1023 treatment could protect RPE cells from H~2~O~2~-induced cell death. ARPE-19 cells were incubated with ALS-L1023 for 24 h. The medium was then removed and replaced with a fresh culture medium containing H~2~O~2~ (0.5 mM) for 4 h. As demonstrated in Figure [2](#F2){ref-type="fig"}A, ALS-L1023 pretreatment prevented RPE cell death from H~2~O~2~-induced oxidative stress in a dose-dependent manner. The cell viability of ARPE-19 cells at concentrations of 0, 6.25, 12.5, 25, 50, 75, 100, 150, and 200 µg/mL ALS-L1023 was 25.9 ± 3.9%, 25.1 ± 2.7%, 25.0 ± 2.3%, 26.3 ± 6.5%, 35.2 ± 4.1%, 56.8 ± 6.8%, 59.8 ± 3.7%, 66.7 ± 4.1%, and 67.1 ± 2.3%, respectively. To investigate the protective effect of ALS-L1023 against H~2~O~2~-induced cell apoptosis, ARPE-19 cells were incubated with ALS-L1023 for 24 h and then exposed to 0.5-mM H~2~O~2~ for 4 h. The apoptosis rate was determined with flow cytometry. ALS-L1023 pretreatment (100 µg/mL) significantly inhibited H~2~O~2~-induced RPE cells apoptosis, as shown in Figure [2](#F2){ref-type="fig"}B. The proportions of Annexin V-positive (apoptosis) cells increased in ARPE-19 cells treated with 0.5-mM H~2~O~2~ alone, compared with the untreated control culture (45.4 ± 9.9% and 2.5 ± 1.5%, respectively, *P*\< 0.05). The pretreatment of ARPE-19 cells with ALS-L1023 before H~2~O~2~ exposure significantly reduced the proportion of Annexin V-positive cells, compared with cultures treated with only H~2~O~2~ (12.3 ± 4.6% and 45.4 ± 9.9%, respectively, *P*\< 0.05) (Fig. [2](#F2){ref-type="fig"}C).

Inhibition of H~2~O~2~-induced intracellular ROS by ALS-L1023
-------------------------------------------------------------

ARPE-19 cells were incubated with ALS-L1023 (100 µg/mL) for 24 h and then treated with H~2~O~2~ (0.5 mM) for 4 h; intracellular ROS levels were measured by DCF fluorescence. Figure [3](#F3){ref-type="fig"}A shows that the DCF fluorescence intensity increased significantly in H~2~O~2~-treated cells. However, pretreatment with ALS-L1023 reduced the DCF fluorescence level (*P*\< 0.05) (Fig. [3](#F3){ref-type="fig"}B).

Suppression of caspase-3/7 activity and PARP cleavage by ALS-L1023
------------------------------------------------------------------

The protective mechanism of ALS-L1023, on ARPE-19 cells against oxidative stress, was assessed by investigating PARP cleavage and caspase-3/7 activity. Caspase-3/7 activity in RPE cells increased 2.9-fold relative to the control after H~2~O~2~ treatment. However, the increased activity of caspase-3/7 was significantly inhibited by pretreatment with 100 µg/mL ALS-L1023 (*P*\< 0.05) (Fig. [4](#F4){ref-type="fig"}A). Figure [4](#F4){ref-type="fig"}B shows that there was a marked increase in the level of cleaved PARP in H~2~O~2~-treated cells compared with the control. The increase in cleaved PARP, however, was inhibited significantly by ALS-L1023 pretreatment (100 µg/mL) (*P*\< 0.05).

ALS-L1023 protects RPE cells by Akt phosphorylation
---------------------------------------------------

Akt activation reportedly plays a crucial role in protecting RPE cells from oxidative stress [@B25]. Therefore, we investigated whether or not Akt phosphorylation could be induced by ALS-L1023. Figure [5](#F5){ref-type="fig"}A showed that ALS-L1023 treatment (100 µg/mL) significantly increased Akt phosphorylation in ARPE-19 cells, whereas H~2~O~2~ treatment did not.

Discussion
==========

In the present study, we evaluated the capacity of *M. officinalis L*. extract to prevent oxidative stress-induced cell death. MTT assay and flow cytometry demonstrated that pretreatment of RPE cells with ALS-L1023 significantly increased cell viability and reduced the apoptosis from oxidative stress. The protection against oxidative stress was mediated by the inhibition of caspase-3, 7 activity and PARP cleavage, which are known to be strong stimulators of apoptosis. The pretreatment of ALS-L1023 generated less intracellular ROS. This protective effect of ALS-L1023 was mediated through the Akt signal transduction pathway. Taken together, *M. officinalis L.* extract effectively protects human RPE cells from H~2~O~2~-induced oxidative stress via anti-apoptotic and antioxidant effects.

Polyphenols are natural plant products found mainly in fruits, vegetables, and plant-based beverages such as wine and tea. The beneficial, antioxidant effects of dietary plant polyphenols have been widely investigated. Epidemiological studies and associated meta-analyses have repeatedly reported that high dietary intake of polyphenols is associated with a decreased risk of developing various chronic diseases, including cardiovascular disease, specific forms of cancer, diabetes, osteoporosis, and neurodegenerative diseases [@B26]-[@B29]. The exact mechanism underlying these effects has not yet been fully elucidated. However, the radical scavenging effects of polyphenols are accepted as an active mechanism for decreasing oxidative stress [@B30], [@B31]. Polyphenols may also be involved in cellular signaling pathways; for example, mitogen-activated protein kinase and PI3K/Akt signaling cascades may influence cellular processes involved in the initiation and progression of cancer, cardiovascular diseases, and neurodegeneration [@B32].

Using a b-carotene-linoleic acid bleaching assay,*M. officinalis L.* extract showed exceptionally high antioxidant activity. This extract is capable of scavenging a wide range of synthetic and naturally occurring free radicals. Its *in vitro* antioxidative activity was superior to that of gallic and caffeic acids, and was as potent as quercetin and butylated hydroxyanisole [@B33]. Compositional fingerprint analysis revealed that *M. officinalis L.* contains a variety of polyphenolic compounds, primarily phenolic acid with hydroxycinnamic acid derivatives and flavonoid with caffeic acid, m-coumaric acid, eriodictyol-7-O-glucoside, naringin, hesperidin, rosmarinic acid, naringenin, and hesperetin [@B33]. The primary substances present in ALS-L1023, flavonoids and hydroxycinnamic acid derivatives possess antioxidant activity; thus, they also contribute to the antioxidant properties of the extract.

The AREDS and AREDS2 formula used to prevent the progression of dry AMD consists basically of antioxidants, including vitamins C and E, zinc, copper, b-carotene, lutein, and zeaxanthin. Zinc and copper are cofactors of superoxide dismutase, which is among the endogenous antioxidant enzymes. A deficiency of copper or zinc increases the activity of the cytochrome P450, and thus enhances ROS generation [@B34]. Vitamins C and E, lutein, and zeaxanthin contribute to ROS inactivation by scavenging them. Flavonoids and hydroxycinnamic acid derivatives in *Melissa officinalis L.* extract are also believed to be scavengers of ROS [@B31]. Figure [3](#F3){ref-type="fig"} shows that ALS-L1023 generated less intracellular ROS in human RPE cells; this promotes the usage of *M. officinalis L.* as a potential therapeutic herb or functional food for dry AMD.

Interestingly, *M. officinalis L.*extract reportedly has an antiangiogenic effect. Previous studies using an animal model for wet AMD showed that systemic administration of the extract inhibited choroidal neovascularization formation by suppressing the expression of vascular endothelial growth factor and matrix metalloproteinase-9 via its antioxidant activity [@B23]. In clinical practice, these effects have the potential to not only prevent the development of dry AMD, but also to prevent conversion from dry to wet AMD.

The Akt signaling pathway is known to be among the most critical pathways in regulating cell survival and metabolism [@B35]. The activation of Akt promotes cellular survival signals that can block apoptosis or withstand apoptotic stimuli. Akt phosphorylates Bcl-2-associated death promoter (BAD), which is a pro-apoptotic protein of the Bcl-2 family. Once phosphorylated, BAD is released from the Bcl-2/Bcl-X complex, which causes it to lose its pro-apoptotic function. It has been reported that the protective effect against oxidative stress-induced apoptosis in human RPE cells is strongly related to the activation of PI3K/Akt [@B36]. In the present study, phosphorylated Akt did not increase in H~2~O~2~-exposed RPE cells, whereas ALS-L1023 treatment significantly enhanced Akt phosphorylation. These results suggest that ALS-L1023 may act as a survival signal through the PI3K/Akt signaling pathway; however, additional studies are required to validate this.

In summary, the present study provided evidence that the extract of *M. officials L.*, ALS-L1023, protects human RPE cells from oxidative stress-induced cell death, which is associated with the suppression of caspase-3/7 activity, ROS generation, PARP cleavage and activation of PI3K/Akt pathways. Therefore, *M. officinalis L*. can be considered as a potential, naturally sourced, therapeutic antioxidant for the prevention of dry AMD.
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![Cytotoxicity of Melissa officinalis L. extract (ALS-L1023) on human retinal pigment epithelial cells (ARPE-19 cells). Cell viability was determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. (A) ARPE-19 cells were treated with different concentrations of ALS-L1023 (0-200 µg/mL). The values are expressed as a percentage of the control (100% cell viability). ALS-L1023 treatment had no significant effect on ARPE-19 cell viability at concentrations ranging from 6.25-200 µg/mL. (B) ARPE-19 cells were treated with different concentrations of H2O2 (0-500 µM). The values are expressed as a percentage of the control (100% cell viability). H2O2 treatment caused a dose-dependent decrease in ARPE-19 cell viability at concentrations ranging from 62.5-500 µM. \*P \< 0.05 vs. the control.](ijmsv13p0139g001){#F1}

![ALS-L1023 increased the cell viability from oxidative-induced stress. (A) ARPE-19 cells were treated with different concentrations of ALS-L1023 for 24 h and then exposed to H2O2 (0.5 mM). \*P \< 0.05 vs. H2O2-exposed cells without ALS-L1023 pretreatment. (B) Flow cytometry showed that the apoptosis rate of ARPE-19 cells treated with ALS-L1023 (100 µg/mL) was much lower than that of cells treated with H2O2 (0.5 mM) alone. (C) Quantification of the rate of apoptotic cells detected with flow cytometry. \*P \< 0.05.](ijmsv13p0139g002){#F2}

![ALS-L1023 inhibits H2O2-induced intracellular reactive oxygen species (ROS) production. (A) ARPE-19 cells were incubated with ALS-L1023 (100 µg/mL) for 24 h and then exposed to H2O2 (0.5 mM). The intracellular ROS was measured with flow cytometry using H2DCF-DA. (B) Mean fluorescence intensity of DCF expressed as means ± SD. ALS-L1023 reduced the generation of ROS in ARPE-19 cells. \*P \< 0.05.](ijmsv13p0139g003){#F3}

![ALS-L1023 protects ARPE-19 cells from H2O2-induced apoptosis via inhibition of caspase-3/7 activity and poly ADP-ribose polymerase (PARP) cleavage. (A) Caspase-3/7 activity after a 4-h exposure to H2O2 was determined by measuring the fluorescence level with and without ALS-L1023 (100 µg/mL) pretreatment. The relative levels of caspase-3/7 activity were expressed as the percentage of untreated control cells (100%). \*P \< 0.05 (B) Effect of ALS-L1023 on PARP cleavage as shown by Western blot analysis. Cleaved PARP expression was elevated by H2O2 (0.5 mM) treatment, whereas ALS-L1023- pretreatment (100 µg/mL) significantly inhibited PARP cleavage. (C) Immunoblotted PARP was quantified by densitometry; data are expressed as the percentage of cleaved PARP relative to the total expression of both the full-form and cleaved PARP. \*P \< 0.05.](ijmsv13p0139g004){#F4}

![ALS-L1023 activates the PI3K/Akt pathway. (A) ARPE-19 cells that were pre-incubated with and without ALS-L1023 (100 µg/mL) were exposed to H2O2 (0.5 mM) for 4 h. Western blot analysis was used to measure the expressions of phosphorylated Akt and Akt. (B) Quantitative analysis was performed by measuring the relative expression level of phosphorylated Akt to Akt. The relative expression level of the control was normalized to 100%. \*P \< 0.05.](ijmsv13p0139g005){#F5}
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